GO:0043124 negative regulation of canonical NF-kappaB signal transduction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043124 describes any process that stops, prevents, or reduces the canonical NF-kappaB signaling cascade, a central inflammatory and survival pathway [2,5].
• Key negative regulators include A20 (TNFAIP3), Nedd4-1, c-IAP proteins, and USP18, which act at distinct steps of the pathway [2,3,6,8].
• Deregulation of this process is linked to autoimmune diseases, chronic inflammation, and lymphoid malignancies such as Hodgkin lymphoma [5,7].
• Experimental models for studying this term include knockout mice, point-mutant knock-in cells, and overexpression systems for negative regulators [2,3,4].
• CRISPR-based knockout, point mutation, knock-in, and overexpression are powerful tools to dissect the causal role of specific genes in this pathway [3,8].
• Understanding negative regulation of canonical NF-kappaB signaling is essential for developing therapies targeting inflammatory and neoplastic diseases [1,5,7].
Description
The canonical NF-kappaB signaling pathway is a master regulator of immune and inflammatory responses, cell survival, and proliferation. Its activity must be tightly controlled to prevent excessive inflammation and oncogenesis. GO:0043124, negative regulation of canonical NF-kappaB signal transduction, encompasses all processes that attenuate this cascade [2,5]. This term is critical for researchers studying immune tolerance, autoimmunity, and cancer, as its disruption can lead to pathological NF-kappaB activation [5,7]. Key negative regulators such as A20 (TNFAIP3) and Nedd4-1 have been shown to terminate NF-kappaB signaling through ubiquitin-dependent mechanisms [2,3]. Understanding these regulatory mechanisms provides insights into disease pathogenesis and identifies potential therapeutic targets [1,7].
negative regulation of canonical NF-kappaB signal transduction At A Glance
| GO ID | GO:0043124 |
|---|---|
| GO term | negative regulation of canonical NF-kappaB signal transduction |
| Ontology | biological_process |
| Synonym | inhibition of I-kappaB kinase/NF-kappaB cascade |
| Major function | Attenuation of canonical NF-kappaB signaling to prevent excessive inflammatory and survival responses |
| Key regulators | A20 (TNFAIP3), Nedd4-1, c-IAP1/2, USP18, Thymosin β4 |
| Associated diseases | Hodgkin lymphoma, autoimmune diseases, myocardial ischemia/reperfusion injury, neurodegeneration |
| Research methods | Knockout, point mutation, knock-in, overexpression, CRISPR screening, immunoblotting, RNA-seq |
What Is GO:0043124?
GO:0043124 is defined as any process that stops, prevents, or reduces the frequency, rate or extent of a canonical NF-kappaB signaling cascade. This includes inhibition of I-kappaB kinase (IKK) activity, stabilization of I-kappaB proteins, or degradation of upstream signaling components, ultimately preventing NF-kappaB nuclear translocation and transcriptional activation [2,3,6].
Why Is negative regulation of canonical NF-kappaB signal transduction Important in Cell Biology?
Negative regulation of canonical NF-kappaB signaling is essential for maintaining immune homeostasis and preventing chronic inflammation and cancer. Dysregulation of this process contributes to autoimmune diseases, inflammatory disorders, and lymphoid malignancies [5,7]. Understanding the molecular mechanisms of negative regulators like A20 and Nedd4-1 offers opportunities for targeted therapies [2,3].
• Prevents excessive inflammatory responses that can damage tissues.
• Controls immune cell activation and tolerance.
• Dysregulation is linked to autoimmune diseases such as rheumatoid arthritis and lupus.
• Loss of negative regulators like A20 is associated with Hodgkin lymphoma and other B-cell malignancies.
• Modulates myocardial ischemia/reperfusion injury through Interleukin-34-NF-kappaB signaling.
• Regulates neuroinflammation and cognitive impairment in Alzheimer's disease models.
• Influences cancer cell pyroptosis via USP18 inhibition.
• Provides targets for anti-inflammatory and anti-cancer therapies [2,7].
• Essential for understanding c-IAP-mediated regulation of TNF receptor family signaling.
• Key for developing CRISPR-based models to study gene function in disease [3,8].
What Happens During negative regulation of canonical NF-kappaB signal transduction?
Ubiquitin-dependent degradation of signaling intermediates
In simple terms: Cells use ubiquitin tags to mark NF-kappaB signaling proteins for destruction, stopping the signal.
Negative regulators such as A20 (TNFAIP3) and Nedd4-1 act as ubiquitin-editing enzymes that modify key signaling molecules like RIPK1 and TRAF6, leading to their degradation and termination of the NF-kappaB cascade [2,3]. A20 removes activating K63-linked ubiquitin chains and adds K48-linked chains, targeting RIPK1 for proteasomal degradation. Nedd4-1 similarly ubiquitinates and downregulates components of the pathway.
Inhibition of IKK complex activity
In simple terms: Proteins block the IKK complex, which is required to activate NF-kappaB, thus shutting down the signal.
The IKK complex (IKKalpha, IKKbeta, NEMO) is essential for phosphorylating I-kappaB and releasing NF-kappaB. Negative regulators can inhibit IKK activity directly or indirectly. For example, c-IAP proteins modulate TNF receptor family-induced NF-kappaB signaling by regulating IKK activation. A20 also inhibits IKK by disrupting the interaction between IKK and upstream adaptors.
Stabilization of I-kappaB proteins
In simple terms: I-kappaB proteins keep NF-kappaB in the cytoplasm; negative regulators prevent their degradation.
I-kappaB proteins bind NF-kappaB and mask its nuclear localization signal. Negative regulation can occur by preventing I-kappaB phosphorylation and degradation. For instance, Thymosin beta4 has been shown to reverse glial cell polarization and cognitive impairment via negative regulation of NF-kappaB signaling, potentially by stabilizing I-kappaB.
Deubiquitination and modulation of signaling complexes
In simple terms: Enzymes remove ubiquitin tags from signaling proteins, altering the signal's strength or duration.
Deubiquitinases such as USP18 can negatively regulate NF-kappaB signaling. Inhibition of USP18 expands the interferon-inducible gene pool and promotes cancer cell pyroptosis, partly through NF-kappaB modulation. Other deubiquitinases like CYLD also remove K63-linked ubiquitin chains from TRAF2, RIP1, and NEMO, thereby inhibiting NF-kappaB activation.
Sequestration and degradation of NF-kappaB subunits
In simple terms: Negative regulators can trap NF-kappaB subunits in the cytoplasm or target them for destruction.
Some negative regulators promote the degradation of NF-kappaB subunits themselves. For example, the ubiquitin ligase Nedd4-1 can target NF-kappaB subunits for degradation, reducing transcriptional output. Additionally, A20 can inhibit NF-kappaB by promoting the degradation of the p65 subunit.
Key Genes Involved in GO:0043124 negative regulation of canonical NF-kappaB signal transduction
The following genes and proteins are key players in the negative regulation of canonical NF-kappaB signal transduction, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFAIP3 (A20) | Ubiquitin-editing enzyme that terminates NF-kappaB signaling by degrading RIPK1 and TRAF6 | Loss-of-function mutations in Hodgkin lymphoma and autoimmune diseases [2,7] |
| NEDD4L (Nedd4-1) | E3 ubiquitin ligase that downregulates NF-kappaB pathway components | Regulates inflammatory responses; potential target in cancer |
| BIRC2 (c-IAP1) | Inhibits NF-kappaB signaling by modulating TNF receptor family-induced IKK activation | Studied in TNF signaling and cancer |
| BIRC3 (c-IAP2) | Similar to c-IAP1, regulates NF-kappaB activation | Involved in lymphoid malignancies [6,7] |
| USP18 | Deubiquitinase that negatively regulates NF-kappaB; inhibition promotes pyroptosis | Cancer therapy target |
| TMSB4X (Thymosin beta4) | Reverses glial cell polarization and cognitive impairment via NF-kappaB inhibition | Neuroinflammation and Alzheimer's disease |
| NFKBIA (I-kappaB alpha) | Inhibitory protein that sequesters NF-kappaB in cytoplasm | Mutations cause ectodermal dysplasia and immunodeficiency |
| NFKBIB (I-kappaB beta) | Inhibitory protein, similar to I-kappaB alpha | Regulates NF-kappaB in various tissues |
| NFKBIE (I-kappaB epsilon) | Inhibitory protein, primarily in lymphoid cells | Associated with immunodeficiency |
| CYLD | Deubiquitinase that removes K63-linked ubiquitin chains from TRAF2, RIP1, NEMO | Tumor suppressor in cylindromatosis |
| TNIP1 (ABIN-1) | Adaptor protein that inhibits NF-kappaB by binding to A20 and ubiquitinated proteins | Autoimmune diseases |
| TNIP2 (ABIN-2) | Similar to ABIN-1, inhibits NF-kappaB | Inflammation |
| IKBKB (IKK beta) | Kinase subunit of IKK complex; negative regulators target its activity | Inflammation and cancer |
| IKBKG (NEMO) | Regulatory subunit of IKK complex; targeted by negative regulators | Immunodeficiency |
| RIPK1 | Kinase that is ubiquitinated and degraded by A20 to stop NF-kappaB signaling | Inflammation and cell death |
| TRAF6 | E3 ubiquitin ligase; A20 removes K63 chains to inhibit NF-kappaB | Bone metabolism and immunity |
| IL34 | Cytokine that aggravates myocardial injury via NF-kappaB; negative regulation counteracts it | Myocardial ischemia/reperfusion injury |
| NFKB1 (p50) | NF-kappaB subunit; its degradation or sequestration negatively regulates signaling | Cancer and inflammation |
How Is negative regulation of canonical NF-kappaB signal transduction Regulated?
The negative regulation of canonical NF-kappaB signaling is itself tightly controlled. For example, A20 expression is induced by NF-kappaB, creating a negative feedback loop. Nedd4-1 activity can be modulated by phosphorylation. USP18 levels are regulated by interferons, and its inhibition enhances NF-kappaB-dependent pyroptosis. Additionally, c-IAP proteins are regulated by TNF receptor signaling and can be targeted by SMAC mimetics.
negative regulation of canonical NF-kappaB signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFAIP3 | Hodgkin lymphoma, autoimmune diseases | Knockout mice, point-mutant knock-in cells [2,7] |
| NEDD4L | Inflammation, cancer | Overexpression and knockout cell lines |
| USP18 | Cancer cell pyroptosis | Knockout and overexpression in cancer cells |
| TMSB4X | Alzheimer's disease, neuroinflammation | APP/PS1 mice with overexpression |
| IL34 | Myocardial ischemia/reperfusion injury | Knockout mice and macrophage-specific models |
Hodgkin Lymphoma
Deregulation of NF-kappaB signaling is a hallmark of Hodgkin lymphoma. Loss-of-function mutations in TNFAIP3 (A20) and other negative regulators lead to constitutive NF-kappaB activation, promoting tumor cell survival and proliferation. Understanding these mechanisms has led to targeted therapies.
Autoimmune and Inflammatory Diseases
Impaired negative regulation of NF-kappaB contributes to autoimmune diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease. Polymorphisms in TNFAIP3 and TNIP1 are associated with increased risk. Enhancing negative regulation is a therapeutic strategy.
Myocardial Ischemia/Reperfusion Injury
Interleukin-34-NF-kappaB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization. Negative regulation of this pathway may protect against injury.
Neurodegeneration
In Alzheimer's disease models, Thymosin beta4 reverses glial cell polarization and cognitive impairment via negative regulation of NF-kappaB signaling, suggesting a protective role.
From negative regulation of canonical NF-kappaB signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of A20 activate NF-kappaB? | TNFAIP3 knockout cell lines and mice |
| How does Nedd4-1 downregulate NF-kappaB? | NEDD4L overexpression and point-mutant (catalytic dead) knock-in |
| Can USP18 inhibition promote pyroptosis via NF-kappaB? | USP18 knockout cancer cells |
| Does Thymosin beta4 reverse cognitive impairment? | TMSB4X overexpression in APP/PS1 mice |
| What is the role of c-IAP in TNF-induced NF-kappaB? | BIRC2/BIRC3 knockout and tagged knock-in |
| Does IL-34 blockade reduce myocardial injury? | IL34 knockout mice and macrophage-specific deletion |
How to Study the negative regulation of canonical NF-kappaB signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunoblotting | Protein levels and phosphorylation of NF-kappaB components | Assessing pathway activation and negative regulator expression [2,3,6] |
| CRISPR knockout screening | Identification of genes whose loss increases NF-kappaB activity | Discovery of novel negative regulators [3,8] |
| RNA-seq | Transcriptional changes upon pathway modulation | Global gene expression analysis |
| Proteomics | Protein interactions and ubiquitination | Mechanistic studies of A20 and Nedd4-1 [2,3] |
| Luciferase reporter assay | NF-kappaB transcriptional activity | High-throughput screening |
| Immunofluorescence | Nuclear translocation of NF-kappaB subunits | Visualizing pathway inhibition |
| Co-immunoprecipitation | Protein-protein interactions | Studying complex formation |
| Flow cytometry | Immune cell polarization and cytokine production | Functional studies in immune cells [1,4] |
Immunoblotting for NF-kappaB Pathway Components
Immunoblot analysis is used to measure I-kappaB alpha phosphorylation and degradation, p65 nuclear translocation, and expression of negative regulators like A20 and Nedd4-1. This method is standard for assessing pathway activity [2,3,6].
CRISPR Screening for Negative Regulators
Genome-wide CRISPR knockout screens can identify novel negative regulators of NF-kappaB signaling. Cells expressing an NF-kappaB-driven reporter are transduced with a sgRNA library, and sgRNAs that increase reporter activity indicate loss of negative regulators [3,8].
RNA-seq and Transcriptomics
RNA sequencing reveals transcriptional changes upon modulation of negative regulators. For example, USP18 inhibition expands interferon-inducible gene pool, which can be monitored by RNA-seq.
Proteomics and Ubiquitin Chain Analysis
Mass spectrometry-based proteomics can identify ubiquitination sites and interacting partners of negative regulators like A20 and Nedd4-1, providing mechanistic insights [2,3].
How CRISPR Can Be Used to Study GO:0043124 negative regulation of canonical NF-kappaB signal transduction
Knockout
CRISPR knockout of negative regulators such as TNFAIP3 or NEDD4L leads to hyperactivation of NF-kappaB signaling, providing causal evidence for their role. These models are used to study inflammation and cancer [2,3].
Point Mutation
Point mutations can be introduced to abrogate catalytic activity of enzymes like A20 or Nedd4-1, allowing dissection of enzymatic versus scaffold functions. For example, catalytically inactive A20 mutants fail to inhibit NF-kappaB.
Knock-in
Knock-in of tagged versions (e.g., HA, FLAG) of negative regulators enables endogenous protein tracking and interaction studies. This is useful for understanding dynamic regulation [3,6].
Overexpression
Overexpression of negative regulators like A20 or Thymosin beta4 can suppress NF-kappaB signaling and ameliorate disease phenotypes in models, validating their therapeutic potential [2,4].
How EDITGENE Supports negative regulation of canonical NF-kappaB signal transduction Research
Researchers studying negative regulation of canonical NF-kappaB signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway control, and to dissect the precise molecular mechanism. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of canonical NF-kappaB signal transduction research.
Frequently Asked Questions About negative regulation of canonical NF-kappaB signal transduction
What is GO:0043124?
GO:0043124 is the Gene Ontology term for negative regulation of canonical NF-kappaB signal transduction, describing any process that stops, prevents, or reduces the canonical NF-kappaB signaling cascade [2,5].
What genes are involved in negative regulation of canonical NF-kappaB signaling?
Key genes include TNFAIP3 (A20), NEDD4L, BIRC2/3 (c-IAP1/2), USP18, and TMSB4X, among others [2,3,4,6,8].
How does A20 negatively regulate NF-kappaB?
A20 is a ubiquitin-editing enzyme that removes activating K63-linked ubiquitin chains from RIPK1 and adds K48-linked chains, targeting it for degradation, thereby terminating NF-kappaB signaling.
What diseases are associated with defective negative regulation of NF-kappaB?
Defective negative regulation is linked to Hodgkin lymphoma, autoimmune diseases, myocardial ischemia/reperfusion injury, and neurodegeneration [1,4,5,7].
What methods are used to study negative regulation of canonical NF-kappaB signaling?
Common methods include immunoblotting, CRISPR knockout screens, RNA-seq, proteomics, and luciferase reporter assays [2,3,6,8].
How can CRISPR be used to study this pathway?
CRISPR can create knockout, point mutation, knock-in, and overexpression models to test the causal role of specific genes in NF-kappaB regulation [2,3,4,8].
What is the role of Nedd4-1 in NF-kappaB signaling?
Nedd4-1 is an E3 ubiquitin ligase that negatively regulates NF-kappaB by targeting pathway components for degradation.
Can overexpression of negative regulators treat inflammatory diseases?
Preclinical studies show that overexpression of A20 or Thymosin beta4 can suppress NF-kappaB and ameliorate disease phenotypes, suggesting therapeutic potential [2,4].
What is the connection between USP18 and NF-kappaB?
USP18 negatively regulates NF-kappaB; its inhibition promotes cancer cell pyroptosis via interferon-inducible gene expansion.
Why is negative regulation of NF-kappaB important for immune tolerance?
It prevents excessive inflammation and maintains immune homeostasis, and its dysregulation leads to autoimmunity.
Conclusion
GO:0043124, negative regulation of canonical NF-kappaB signal transduction, is a critical biological process that maintains immune homeostasis and prevents disease. Key negative regulators such as A20, Nedd4-1, and USP18 act through ubiquitin-dependent and independent mechanisms to attenuate NF-kappaB signaling [2,3,8]. Dysregulation of this process is implicated in cancer, autoimmunity, and neurodegeneration [1,4,5,7]. CRISPR-based models are invaluable for dissecting these mechanisms and developing targeted therapies. EDITGENE provides comprehensive services to support such research.
References
- 1. Zhuang L et al.. 2023. Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.. EBioMedicine 95:104744 PMID: 37556943
- 2. Pujari R et al.. 2013. A20-mediated negative regulation of canonical NF-κB signaling pathway.. Immunol Res 57(1-3):166-71 PMID: 24242761
- 3. Persaud A et al.. 2026. Negative regulation of the NF-κB pathway by the ubiquitin ligase Nedd4-1(NE).. Commun Biol 9(1) PMID: 41654613
- 4. Wang M et al.. 2021. Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice.. J Neuroinflammation 18(1):146 PMID: 34183019
- 5. van Delft MA et al.. 2015. The contribution of NF-κB signalling to immune regulation and tolerance.. Eur J Clin Invest 45(5):529-39 PMID: 25735405
- 6. Varfolomeev E et al.. 2021. Immunoblot Analysis of the Regulation of TNF Receptor Family-Induced NF-κB Signaling by c-IAP Proteins.. Methods Mol Biol 2366:109-123 PMID: 34236635
- 7. Weniger MA et al.. 2016. NF-κB deregulation in Hodgkin lymphoma.. Semin Cancer Biol 39:32-9 PMID: 27221964
- 8. Arimoto KI et al.. 2023. Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis.. Nat Commun 14(1):251 PMID: 36646704
